BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 29 OCTOBER 2009 at 11.00 a.m. Resolutions of the Extraordinary General Meeting of Biotie Therapies Corp. The Extraordinary General Meeting of Biotie Therapies Corp. was held on 29 October 2009. The Meeting resolved to approve all proposals. The Board of Directors The number of the members of the Board of Directors was resolved to be eight and Dr Peter Fellner was elected as a new member of the Board of Directors. Amendment to the Articles of Association The Extraordinary General Meeting resolved to amend, due to the amendment to the Finnish Companies Act, the method and minimum period for publishing the summons to the general meetings in the Article 10 of the company's Articles of Association. After the amendment the Article 10 reads as follows: "10 § Summons to the meetings The shareholders of the company are summoned to the shareholders' meeting by publishing the summons on the company's website. The summons shall be published not earlier than two (2) months before the last registration date mentioned in the summons and not later than three (3) weeks prior to the date of the meeting. In addition, the Board of Directors shall publish a summary notice of the shareholders' meeting in one or more national daily newspaper, or by sending the notice of the shareholders' meeting as a registered letter or other verifiable way to the shareholders' address, which is registered in the share register." Authorisation of the Board of Directors to decide on an issuance of shares as well as the issuance of options and other special rights entitling to shares The Extraordinary General Meeting authorised the Board of Directors to resolve on one or more issues which contains the right to issue new shares or dispose of the shares in the possession of the company and to issue options or other specific rights to the shares pursuant to chapter 10 of the Companies Act. The authorisation consists of up to 72,000,000 shares in the aggregate. The authorisation does not exclude the Board of Directors' right to decide on a directed issue. The authorisation may be used for material arrangements from the company's point of view, such as financing or implementing business arrangements or investments or for other such purposes determined by the Board of Directors in which case a weighty financial reason for issuing shares, options or other specific rights and possibly directing a share issue exists. The authorisation cannot, however, be used to create new share-based incentive schemes. The Board of Directors was authorised to resolve on all other terms and conditions of a share issue, options and other specific share entitlements as referred to in chapter 10 of the Companies Act, including the payment period, determination grounds for the subscription price and subscription price or allocation of shares, option rights or specific rights free of charge or that the subscription price may be paid besides in cash also by other assets either partially or entirely. The authorisation is effective until 30 June 2010 and it supersedes earlier authorisations. The minutes of the meeting will be available on the company's website as from 12 November 2009. Turku, 29 October 2009 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Timo Veromaa, President and CEO, Biotie Therapies Corp. tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com www.biotie.com DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media
Resolutions of the Extraordinary General Meeting of Biotie Therapies Corp.
| Source: Biotie Therapies